Evidence map›Paper›PMID 27059723›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2016

Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT).

Tadanobu Nagaya, Yuko Nakamura, Kazuhide Sato, Toshiko Harada, Peter L Choyke, Hisataka Kobayashi

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Article
  4. Review
  5. Review
  6. Article
  7. Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tadanobu NagayaMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States.
Yuko NakamuraMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States.
Kazuhide SatoMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States.
Toshiko HaradaMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States.
Peter L ChoykeMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States.
Hisataka KobayashiMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States. Electronic address: kobayash@mail.nih.gov.
National Cancer Institute · USCenter for Cancer Research · US

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011513
6 · The paper itself

Abstract

Near infrared photoimmunotherapy (NIR-PIT), a targeted cancer therapy which uses an antibody-photo absorber conjugate (APC) and near infrared light exposure, dramatically improves nano-drug delivery into treated tumor beds due to enhanced vascular permeability. We investigated the micro-distribution of APCs in a variety of NIR-PIT treated tumors. Either cetuximab (cet) or trastuzumab (tra) conjugated with IR700 (cet-tra-IR700) was administered, as appropriate, to each mouse model of tumor. Tumor-bearing mice implanted with A431-GFP, MDAMB468-GFP, 3T3Her2-GFP or N87-GFP were separated into 5 groups: group 1=no treatment; group 2=cet-tra-IR700 i.v., no light exposure; group 3=cet-tra-IR700 i.v., NIR light exposure; group 4=cet-tra-IR700 i.v. and additional cet-tra-IR700 i.v. at 24h but no light exposure; group 5=cet-tra-IR700 i.v., NIR light exposure and additional cet-tra-IR700 i.v. immediately after NIR but no additional NIR light exposure. In vivo, ex vivo and microscopic fluorescence imaging was performed. Fluorescence from the surface of the tumor (s-tumor) was compared to fluorescence from deeper areas of the tumor (d-tumor). In general, there was no significant difference in the fluorescence intensity of GFP in the tumors among all groups, however the highest IR700 fluorescence intensity was consistently shown in group 5 tumors due to added APC after NIR-PIT. Fluorescence microscopy in all tumor types demonstrated that GFP relative fluorescence intensity (RFI) in s-tumor was significantly lower in group 3 and 5 (NIR-PIT groups) than in group 1, 2, and 4 (no NIR-PIT) yet there was no significant difference in d-tumor RFI among all groups. IR700 fluorescent RFI in the d-tumor was highest in group 5 (NIR-PIT+additional APC) compared to the other groups. Cell killing after NIR-PIT was primarily on the surface, however, APCs administered immediately after NIR-PIT penetrated deeper into tissue resulting in improved cell killing after a 2nd NIR-PIT session. This phenomenon is explained by increased vascular permeability immediately after NIR-PIT.

Indexed as

LightAnimalsAntineoplastic AgentsCarbocyaninesCell Line, TumorCetuximabFemaleHumansImmunotherapyMice, NudeMicroscopy, FluorescenceNeoplasmsOrganophosphorus CompoundsPhotochemotherapyPhotosensitizing AgentsTrastuzumabAntineoplastic AgentsCarbocyaninesCetuximabIRD 700Organophosphorus CompoundsPhotosensitizing AgentsTrastuzumabDrug deliveryEnhanced permeability and retention effectMicro distributionNear infrared lightPhotoimmunotherapy

Identifiers

PMID27059723
PMCPMC4893891
OpenAlexW2321158401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.